Floatz logo

(+)-VINCRISTINE

Metastatic Urothelial Carcinoma

PfizerSmall moleculePhase 3Active
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
60/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Metastatic Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Vasgene Therapeutics, Inc
Phase 2/3BB
Irinotecan
Pfizer
Phase 3BB
Durvalumab
Alliance for Clinical Trials in Oncology
Phase 3BB
Olaparib
Rahul Aggarwal
Phase 2BB
Recombinant Ephb4-Hsa Fusion Protein
Vasgene Therapeutics, Inc
Phase 2/3CCC

View all 21 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →